It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The intestinal epithelial monolayer, at the boundary between microbes and the host immune system, plays an important role in the development of inflammatory bowel disease (IBD), particularly as a target and producer of pro-inflammatory TNF. Chronic overexpression of TNF leads to IBD-like pathology over time, but the mechanisms driving early pathogenesis events are not clear. We studied the epithelial response to inflammation by combining mathematical models with in vivo experimental models resembling acute and chronic TNF-mediated injury. We found significant villus atrophy with increased epithelial cell death along the crypt-villus axis, most dramatically at the villus tips, in both acute and chronic inflammation. In the acute model, we observed overexpression of TNF receptor I in the villus tip rapidly after TNF injection and concurrent with elevated levels of intracellular TNF and rapid shedding at the tip. In the chronic model, sustained villus atrophy was accompanied by a reduction in absolute epithelial cell turnover. Mathematical modelling demonstrated that increased cell apoptosis on the villus body explains the reduction in epithelial cell turnover along the crypt-villus axis observed in chronic inflammation. Cell destruction in the villus was not accompanied by changes in proliferative cell number or division rate within the crypt. Epithelial morphology and immunological changes in the chronic setting suggest a repair response to cell damage although the villus length is not recovered. A better understanding of how this state is further destabilised and results in clinical pathology resembling IBD will help identify suitable pathways for therapeutic intervention.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Quadram Institute Bioscience, Gut Health and Food Safety Research Programme, Norwich, United Kingdom (GRID:grid.40368.39) (ISNI:0000 0000 9347 0159)
2 Wellcome Sanger Institute, Hinxton, United Kingdom (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382)
3 University of Sheffield, School of Mathematics and Statistics, Sheffield, United Kingdom (GRID:grid.11835.3e) (ISNI:0000 0004 1936 9262); University of Sheffield, Bateson Centre, Sheffield, United Kingdom (GRID:grid.11835.3e) (ISNI:0000 0004 1936 9262)
4 University of Oxford, Wolfson Centre for Mathematical Biology, Mathematical Institute, Oxford, United Kingdom (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
5 University of East Anglia, Norwich Medical School, Norwich, United Kingdom (GRID:grid.8273.e) (ISNI:0000 0001 1092 7967)
6 Quadram Institute Bioscience, Gut Health and Food Safety Research Programme, Norwich, United Kingdom (GRID:grid.40368.39) (ISNI:0000 0000 9347 0159); IMED Biotech Unit, AstraZeneca, Drug Safety and Metabolism, Cambridge, United Kingdom (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381)